Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark B Leick

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Science Translational Medicine|June 4, 2025
IFN-γ-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor modelsStefanie R Bailey, Hana N Takei, Giulia Escobar, et al.
Mabs|May 15, 2023
10th antibody industrial symposium: new developments in antibody and adoptive cell therapiesAna Antunes, Luis Alvarez-Vallina, Federico Bertoglio, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
Nature|September 24, 2025
In vivo CRISPR screens identify modifiers of CAR T cell function in myelomaNelson H Knudsen, Giulia Escobar, Felix Korell, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Transplantation and Cellular Therapy|October 9, 2025
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>Melissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Transplantation and Cellular Therapy|March 11, 2023
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeMelissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Science Translational Medicine|June 4, 2025
IFN-γ-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor modelsStefanie R Bailey, Hana N Takei, Giulia Escobar, et al.
Mabs|May 15, 2023
10th antibody industrial symposium: new developments in antibody and adoptive cell therapiesAna Antunes, Luis Alvarez-Vallina, Federico Bertoglio, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
Nature|September 24, 2025
In vivo CRISPR screens identify modifiers of CAR T cell function in myelomaNelson H Knudsen, Giulia Escobar, Felix Korell, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Transplantation and Cellular Therapy|October 9, 2025
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>Melissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Transplantation and Cellular Therapy|March 11, 2023
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeMelissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Pageof 6